Nabriva Therapeutics plc Purchase Obligation
Nabriva Therapeutics plc had Purchase Obligation of $39.75 million as of 2023-03-31, per its 10-Q filed 2023-05-22.
Discontinued › Notes › Commitment and Contingencies › Purchase Obligation, Fiscal Year Maturity
us-gaap:PurchaseObligation · last filed 2023-05-22
- 2023-03-31: Purchase Obligation $39.75M.
- 2022-12-31: Purchase Obligation $39.15M.
- 2021-12-31: Purchase Obligation $53.98M.
| Period end | Purchase Obligation |
|---|---|
| 2023-03-31 | $39.75M 10-Q · filed 2023-05-22 |
| 2022-12-31 | $39.15M 10-K · filed 2023-04-17 |
| 2021-12-31 | $53.98M 10-K · filed 2022-03-29 |